{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:29:43Z","timestamp":1790958583325,"version":"4.1.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":613,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1093\/annonc\/mdy032","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T20:15:00Z","timestamp":1516392900000},"page":"588-601","source":"Crossref","is-referenced-by-count":12,"title":["Next-generation immunotherapies for lymphoma: one foot in the future"],"prefix":"10.1016","volume":"29","author":[{"given":"G.","family":"Manson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdy032_bb0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"issue":"23","key":"10.1093\/annonc\/mdy032_bb0015","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy032_bb0020","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1093\/annonc\/mdy032_bb0025","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdy032_bb0030","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/leu.2014.201","article-title":"The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing","volume":"28","author":"Liu","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1093\/annonc\/mdy032_bb0035","first-page":"37","article-title":"Absence of HLA class I expression by Reed-Sternberg cells","volume":"145","author":"Poppema","year":"1994","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1093\/annonc\/mdy032_bb0040","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1182\/blood.V87.9.3844.bloodjournal8793844","article-title":"Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin\u2019s disease","volume":"87","author":"Oudejans","year":"1996","journal-title":"Blood"},{"issue":"11","key":"10.1093\/annonc\/mdy032_bb0045","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1093\/annonc\/mdy032_bb0050","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1093\/annonc\/mdy032_bb0055","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy032_bb0060","author":"Engert","year":"2017"},{"issue":"19","key":"10.1093\/annonc\/mdy032_bb0065","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1093\/annonc\/mdy032_bb0070","first-page":"205","article-title":"Checkmate 205\u202f: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) \u2014a phase 2 study","volume":"101","author":"Younes","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"10.1093\/annonc\/mdy032_bb0075","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1093\/annonc\/mdy032_bb0080","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/annonc\/mdx341","article-title":"Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience","volume":"28","author":"Bek\u00f6z","year":"2017","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1093\/annonc\/mdy032_bb0085","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1093\/annonc\/mdy032_bb0090","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post\u2013allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"issue":"S2","key":"10.1093\/annonc\/mdy032_bb0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hon.2437_54","article-title":"Blockage of the PD-1 checkpoint with anti-PD-L1 antibody avelumab is sufficient for clinical activity in relapsed\/refractory classical Hodgkin lymphoma (CHL)","volume":"35","author":"Chen","year":"2017","journal-title":"Hematol Oncol"},{"issue":"S2","key":"10.1093\/annonc\/mdy032_bb0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hon.2437_73","article-title":"Interim results from a phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"35","author":"Herrera","year":"2017","journal-title":"Hematol Oncol"},{"issue":"S2","key":"10.1093\/annonc\/mdy032_bb0105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hon.2437_72","article-title":"Safety and efficacy of combination of brentuximab vedotin and nivolumab in relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412)","volume":"35","author":"Diefenbach","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mdy032_bb0110","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.649.649","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","author":"Herrera","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1093\/annonc\/mdy032_bb0115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039)","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1093\/annonc\/mdy032_bb0120","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1093\/annonc\/mdy032_bb0125","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1093\/annonc\/mdy032_bb0130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1093\/annonc\/mdy032_bb0135","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1093\/annonc\/mdy032_bb0140","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1093\/annonc\/mdy032_bb0145","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1093\/annonc\/mdy032_bb0150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"issue":"S2","key":"10.1093\/annonc\/mdy032_bb0155","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2437_49","article-title":"Efficacy and safety of pembrolizumab in relapsed\/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial","volume":"35","author":"Zinzani","year":"2017","journal-title":"Hematol Oncol"},{"issue":"23","key":"10.1093\/annonc\/mdy032_bb0160","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1093\/annonc\/mdy032_bb0165","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1093\/annonc\/mdy032_bb0170","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V128.22.181.181","article-title":"Pembrolizumab for treatment of relapsed\/refractory mycosis fungoides and sezary syndrome: clinical efficacy in a Citn multicenter phase 2 study","volume":"128","author":"Khodadoust","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1093\/annonc\/mdy032_bb0175","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1093\/annonc\/mdy032_bb0180","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdy032_bb0185","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1093\/annonc\/mdy032_bb0190","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell Engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdy032_bb0195","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of bispecific T-cell engager (BiTE(R)) antibody blinatumomab in relapsed\/refractory diffuse large B cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1093\/annonc\/mdy032_bb0200","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V128.22.621.621","article-title":"Phase 1 study of REGN1979, an anti-CD20 x anti-CD3 bispecific monoclonal antibody, in patients with CD20+ B-cell malignancies previously treated with CD20-directed antibody therapy","volume":"128","author":"Bannerji","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1093\/annonc\/mdy032_bb0205","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/bjh.13242","article-title":"Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies","volume":"169","author":"Schuster","year":"2015","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1093\/annonc\/mdy032_bb0210","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1093\/annonc\/mdy032_bb0215","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"issue":"16","key":"10.1093\/annonc\/mdy032_bb0220","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1093\/annonc\/mdy032_bb0225","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy032_bb0230","unstructured":"FDA - U.S. Food & Drug Administration. Press Announcements - FDA approval brings first gene therapy to the United States. 2017."},{"key":"10.1093\/annonc\/mdy032_bb0235","unstructured":"FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm581216.htm."},{"issue":"6","key":"10.1093\/annonc\/mdy032_bb0240","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdy032_bb0245","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdy032_bb0250","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdy032_bb0255","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"13 Suppl","key":"10.1093\/annonc\/mdy032_bb0260","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hon.2437_7","article-title":"Axicabtagene ciloleucelL (AXI-CEL; KTE-C19) in patient with refractory aggressive non-Hodgkin lymphoma (NHL): primary results of the pivotal trial ZUMA-1","volume":"35","author":"Neelapu","year":"2017","journal-title":"Hematol Oncol"},{"issue":"26","key":"10.1093\/annonc\/mdy032_bb0265","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"S2","key":"10.1093\/annonc\/mdy032_bb0270","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hon.2437_6","article-title":"Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)\u2013 an interim analysis","volume":"35","author":"Schuster","year":"2017","journal-title":"Hematol Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdy032_bb0275","first-page":"577 LP","article-title":"Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"130","author":"Schuster","year":"2017","journal-title":"Blood"},{"issue":"S2","key":"10.1093\/annonc\/mdy032_bb0280","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hon.2437_127","article-title":"High CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T CELL product JCAR017 (TRANSCEND NHL 001)","volume":"35","author":"Abramson","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mdy032_bb0285","author":"Abramson","year":"2017"},{"issue":"8","key":"10.1093\/annonc\/mdy032_bb0290","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mdy032_bb0295","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy032_bb0300","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1093\/annonc\/mdy032_bb0305","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdy032_bb0310","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.59.59","article-title":"Nivolumab combined with ibrutinib for CLL and Richter transformation: a phase II trial","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"26","key":"10.1093\/annonc\/mdy032_bb0315","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"355","key":"10.1093\/annonc\/mdy032_bb0320","doi-asserted-by":"crossref","first-page":"355ra116.","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1093\/annonc\/mdy032_bb0325","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1093\/annonc\/mdy032_bb0330","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"issue":"9","key":"10.1093\/annonc\/mdy032_bb0335","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor\u2013redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1093\/annonc\/mdy032_bb0340","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/imr.12572","article-title":"Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases","volume":"280","author":"Frey","year":"2017","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1093\/annonc\/mdy032_bb0345","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"issue":"4","key":"10.1093\/annonc\/mdy032_bb0350","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1046\/j.1365-2141.2000.01967.x","article-title":"Gamma-ray irradiation induces B7.1 expression in myeloid leukaemic cells","volume":"108","author":"Vereecque","year":"2000","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1093\/annonc\/mdy032_bb0355","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1093\/annonc\/mdy032_bb0360","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med"},{"issue":"5","key":"10.1093\/annonc\/mdy032_bb0365","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"10.1093\/annonc\/mdy032_bb0370","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jjco\/hyp112","article-title":"Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer","volume":"39","author":"Soeda","year":"2009","journal-title":"Jpn J Clin Oncol"},{"issue":"21","key":"10.1093\/annonc\/mdy032_bb0375","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence","volume":"20","author":"de Biasi","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdy032_bb0380","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","article-title":"Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy","volume":"1","author":"DeNardo","year":"2011","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1093\/annonc\/mdy032_bb0385","first-page":"6505","article-title":"Effect of neoadjuvant chemoradiation on tumor-infiltrating\/associated lymphocytes in locally advanced rectal cancers","volume":"34","author":"Lim","year":"2014","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1093\/annonc\/mdy032_bb0390","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/01.cji.0000203081.43235.d7","article-title":"Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum","volume":"29","author":"Lefebvre","year":"2006","journal-title":"J Immunother"},{"issue":"9","key":"10.1093\/annonc\/mdy032_bb0395","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1634\/theoncologist.2008-0089","article-title":"The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy","volume":"13","author":"Zhou","year":"2008","journal-title":"Oncologist"},{"issue":"8","key":"10.1093\/annonc\/mdy032_bb0400","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"M\u00fcller","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1093\/annonc\/mdy032_bb0405","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdy032_bb0410","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood-2009-05-223958","article-title":"Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion","volume":"114","author":"Houot","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1093\/annonc\/mdy032_bb0415","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1476-5381.2011.01753.x","article-title":"Pharmacological modulation of GITRL\/GITR system: therapeutic perspectives","volume":"165","author":"Nocentini","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1093\/annonc\/mdy032_bb0420","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nri3790","article-title":"Clinical blockade of PD1 and LAG3\u2013potential mechanisms of action","volume":"15","author":"Nguyen","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1093\/annonc\/mdy032_bb0425","doi-asserted-by":"crossref","first-page":"e1011484.","DOI":"10.1080\/2162402X.2015.1011484","article-title":"Kick-starting the cancer-immunity cycle by targeting CD40","volume":"4","author":"Ellmark","year":"2015","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1093\/annonc\/mdy032_bb0430","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.4049\/jimmunol.1300409","article-title":"Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice","volume":"191","author":"He","year":"2013","journal-title":"J Immunol"},{"issue":"8","key":"10.1093\/annonc\/mdy032_bb0435","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/CJI.0b013e3181ee238f","article-title":"Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8+ T cells","volume":"33","author":"Roberts","year":"2010","journal-title":"J Immunother"},{"issue":"2","key":"10.1093\/annonc\/mdy032_bb0440","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.coi.2012.01.001","article-title":"NK cell MHC class I specific receptors (KIR): from biology to clinical intervention","volume":"24","author":"Thielens","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"10.1093\/annonc\/mdy032_bb0445","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"issue":"10","key":"10.1093\/annonc\/mdy032_bb0450","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell\u2013mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat Med"},{"issue":"4","key":"10.1093\/annonc\/mdy032_bb0455","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"Timeline: the evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1093\/annonc\/mdy032_bb0460","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1093\/annonc\/mdy032_bb0465","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI31178","article-title":"Indoleamine 2, 3-dioxygenase and tumor-induced tolerance","volume":"117","author":"Munn","year":"2007","journal-title":"J Clin Invest"},{"issue":"13","key":"10.1093\/annonc\/mdy032_bb0470","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood-2014-08-593137","article-title":"Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma","volume":"125","author":"Sagiv-Barfi","year":"2015","journal-title":"Blood"},{"issue":"15","key":"10.1093\/annonc\/mdy032_bb0475","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy032_bb0480","article-title":"PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux","author":"O\u2019Donnell","year":"2017","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"10.1093\/annonc\/mdy032_bb0485","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"issue":"49","key":"10.1093\/annonc\/mdy032_bb0490","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/onc.2015.46","article-title":"Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity","volume":"34","author":"Cao","year":"2015","journal-title":"Oncogene"},{"issue":"24","key":"10.1093\/annonc\/mdy032_bb0495","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1158\/0008-5472.CAN-13-0890","article-title":"An intact immune system is required for the anticancer activities of histone deacetylase inhibitors","volume":"73","author":"West","year":"2013","journal-title":"Cancer Res"},{"issue":"7577","key":"10.1093\/annonc\/mdy032_bb0500","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1093\/annonc\/mdy032_bb0505","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","article-title":"The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy","volume":"20","author":"Zingg","year":"2017","journal-title":"Cell Rep"},{"issue":"18","key":"10.1093\/annonc\/mdy032_bb0510","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/0008-5472.CAN-15-1122","article-title":"STAT3 inhibition enhances the therapeutic efficacy of immunogenic chemotherapy by stimulating type 1 interferon production by cancer cells","volume":"75","author":"Yang","year":"2015","journal-title":"Cancer Res"},{"issue":"7668","key":"10.1093\/annonc\/mdy032_bb0515","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdy032_bb0520","article-title":"Combining DNA damaging therapeutics with immunotherapy: more haste, less speed","author":"Brown","year":"2017","journal-title":"Nat Publ Gr"},{"issue":"6","key":"10.1093\/annonc\/mdy032_bb0525","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1189\/jlb.1012501","article-title":"TLR agonists: our best frenemy in cancer immunotherapy","volume":"93","author":"Kaczanowska","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1093\/annonc\/mdy032_bb0530","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejca.2016.12.028","article-title":"Rationale for stimulator of interferon genes\u2013targeted cancer immunotherapy","volume":"75","author":"Rivera","year":"2017","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdy032_bb0535","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11427-016-9066-0","article-title":"STING-mediated DNA sensing in cancer immunotherapy","volume":"60","author":"Zhou","year":"2017","journal-title":"Sci China Life Sci"},{"issue":"2","key":"10.1093\/annonc\/mdy032_bb0540","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2013.220","article-title":"Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies","volume":"22","author":"Workenhe","year":"2014","journal-title":"Mol Ther"},{"key":"10.1093\/annonc\/mdy032_bb0545","doi-asserted-by":"crossref","first-page":"e2134.","DOI":"10.1038\/cddis.2016.47","article-title":"The oncolytic peptide LTX-315 triggers immunogenic cell death","volume":"7","author":"Zhou","year":"2016","journal-title":"Cell Death Dis"},{"issue":"12","key":"10.1093\/annonc\/mdy032_bb0550","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.4155\/fmc-2017-0088","article-title":"LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment","volume":"9","author":"Sveinbj\u00f8rnsson","year":"2017","journal-title":"Future Med Chem"},{"issue":"1","key":"10.1093\/annonc\/mdy032_bb0555","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-015-0188-3","article-title":"AFM13: a first-in-class tetravalent bispecific anti-CD30\/CD16A antibody for NK cell-mediated immunotherapy","volume":"8","author":"Wu","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy032_bb0560","doi-asserted-by":"crossref","first-page":"17943","DOI":"10.1038\/srep17943","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Sci Rep"},{"issue":"8","key":"10.1093\/annonc\/mdy032_bb0565","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"issue":"14","key":"10.1093\/annonc\/mdy032_bb0570","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/sj.gt.3301234","article-title":"Feeding dendritic cells with tumor antigens: self-service buffet or \u00e0 la carte?","volume":"7","author":"Melero","year":"2000","journal-title":"Gene Ther"},{"issue":"9","key":"10.1093\/annonc\/mdy032_bb0575","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1093\/annonc\/mdy032_bb0580","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat Rev Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419355243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419355243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/3\/588\/24530985\/mdy032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:01:49Z","timestamp":1624698109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419355243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0923753419355243"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy032","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}